After riding out calls for change from Elliot Management earlier in the year, GlaxoSmithKline is facing renewed pressure from a new activist investor, Bluebell Capital Partners.
In a letter to the company’s board of directors, Bluebell called on GSK to require Emma Walmsley to reapply for...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
